Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021


HomeHemovent GmbHCompletion of GLP Standardized in vivo Trial for Long-Term Use of Its...

Completion of GLP Standardized in vivo Trial for Long-Term Use of Its Next-Gen ExtraCorporeal Membrane Oxygenation (ECMO) System Mobybox™ Produces “Stunning Results” Reports Hemovent

Key endpoints in all-six subjects — no hemolysis, no thrombosis at low anticoagulation and no functional device wear — will be used for CE mark registration and FDA submission of Mobybox™, the initial application of Hemovent’s Bionique™ platform. “The oxygenators and pumps looked as if they had just left cleanroom manufacturing, while post-study blood lab gas exchange rates were identical to those of a new oxygenator: stunning results,” said Dr. Oliver Marseille, a cofounder and CTO of Hemovent and a cofounder of CircuLite® (HeartWare®).

Today Hemovent GmbH announced t has successfully completed a GLP standardized in vivo study for long-term (7 days) use of its novel and portable Bionique artificial lung technology platform, designed for a wide range of indications: from ExtraCorporeal Life Support (ECLS) to ExtraCorporeal CO2 Removal (ECCO2R).

“We are extremely pleased by our study results, which we will use for the basis of a CE mark registration submission this year as well as our subsequent FDA submission,” said Christof Lenz, a co-founder and CEO of Hemovent. “Completing this study, especially with these dramatic results, constitutes an important benchmark for Hemovent toward commercializing our Bionique technology, which is positioned to disrupt a billion-dollar market, whose standard therapy is complex to use, costly to purchase, and not portable.

“We expect that when our initial technology application, Mobybox, is commercially available, it will dramatically simplify ECMO usage, not only for life support applications (ECLS) but also as an effective therapy for respiratory failure indications including ECCO2R protocols,” added Lenz.

These types of applications are also known as ExtraCorporeal Membrane Oxygenation (ECMO): the establishment of an artificial external blood circuit with a portable pump and gas exchanger system in order to support the lung function only or even establish a full cardiopulmonary bypass.

Hemovent is an emerging medical device company that has developed the world’s smallest and first self-contained, fully portable device for ExtraCorporeal Membrane Oxygenation (ECMO) /ExtraCorporeal Life Support (ECLS) applications designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure.

CAUTION: The Hemovent ECMO/ ECLS System is not approved for human use.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy